The Correlation between Endotoxin, D-Lactate, and Diamine Oxidase with Endoscopic Activity in Inflammatory Bowel Disease

Qi Zhang, Xin Gao, Jixiong Wu, and Min Chen

1Department of General Medicine, Renmin Hospital of Wuhan University, Wuhan 430060, China
2Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan 430060, China
3Department of Gastroenterology, Huanggang Central Hospital, Huanggang 438000, China
4Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan 430062, China

Correspondence should be addressed to Jixiong Wu; 2307465396@qq.com and Min Chen; chenmin8106@whu.edu.cn

1Department of General Medicine, Renmin Hospital of Wuhan University, Wuhan 430060, China
2Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan 430060, China
3Department of Gastroenterology, Huanggang Central Hospital, Huanggang 438000, China
4Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan 430062, China

Received 2 April 2022; Revised 9 August 2022; Accepted 22 August 2022; Published 16 September 2022

Academic Editor: Ghulam Ashraf

Copyright © 2022 Qi Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background and Objective. The disease activity monitoring of inflammatory bowel disease (IBD) plays a crucial role for making therapeutic strategies. Endoscopy has been recognized as a gold standard for evaluating disease activity of IBD. However, this method is invasive. Currently, a noninvasive biomarker that could replace endoscope is needed in clinical practice. In this study, we examined whether the diamine oxidase (DAO), D-lactate, and endotoxin (ETX) could monitor the disease activity and predict endoscopic remission in patient with IBD.

Methods. A total of 149 eligible IBD patients including 82 Crohn disease (CD) and 67 Ulcerative colitis (UC) who had received both endoscopic examination and intestinal barrier function detection in our hospital were enrolled in this study. Endoscopic activity was estimated by the Simple Endoscopic Score (SES-CD) for Crohn’s Disease and the ulcerative colitis endoscopic index of severity (UCEIS) for ulcerative colitis. The predictive value and optimal predictive thresholds for those biomarkers were determined by receiver operating characteristic analysis.

Results. For UC patients, DAO, D-lactate, and ETX showed better correlation with UCEIS than erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) and exhibited satisfactory predictive value in predicting remission. Among patients with CD, DAO and ETX not only showed a better correlation than WBC, ESR, and CRP with SES-CD but also capable to identify more severe patients. Conclusion. DAO and ETX could be used to distinguish different endoscopic activity of CD. DAO, D-lactate, and ETX could predict UC endoscopic remission.

1. Introduction

The assessment of disease activity of inflammatory bowel disease (IBD) has crucial implications for making therapeutic strategies and predicting prognosis in clinical practice. Endoscopic remission in patients with IBD is associated with durable remission and is considered the ultimate goal of IBD therapy [1]. The gold standard of evaluating disease activity of IBD is endoscopic and histopathological examination. However, endoscopy examination with biopsy is an invasive, expensive, and time-consuming procedure. In clinical practice, some patients may be reluctant to handle fecal material. Therefore, it is important to find reliable serum biomarkers which can replace endoscopic examination to monitor disease activities or predict endoscopic remission.

The traditional biological activity markers of IBD that are widely used in clinical practice to evaluate disease activity of IBD are C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). However, both of them lack intestinal specificity. Some studies showed that the relationship between CRP and disease activity of Crohn disease (CD) was weak [2, 3]. Another study found that there was no relation between serum CRP and endoscopic activity of ulcerative colitis (UC), and ESR was the more accurate to assess the endoscopic activity than CRP with low sensitivity and specificity [4]. The effect of CRP and ESR in evaluating IBD is limited as previously described.
An accurate and reliable noninvasive serum biomarker for evaluating the endoscopic activity of IBD has not yet been identified.

The barrier function of the intestine was found to play a significant role in IBD [7–9]. Previous studies have suggested that monitoring the change of intestinal barrier function may help evaluate disease status of IBD [10–12]. Diamine oxidase (DAO), D-lactate, and endotoxin (ETX) are three biomarkers which are most commonly used to assess the function of intestinal barrier [13–15]. Previous studies have identified that DAO, D-lactate, and ETX are relatable with IBD activity. Even so, whether these biomarkers were capable to replace the invasive endoscopic techniques was still unclear. In this study, we studied the correlation of DAO, D-lactate, and ETX levels with endoscopic activity in patients with IBD, aiming to assess whether DAO, D-lactate, and ETX could monitor the disease activity of IBD and predict the endoscopic remission.

2. Patients and Methods

2.1. Patients. A total of 149 IBD patients (82 CD, 67 UC) who have undergone both endoscopic examination and intestinal barrier function detection in the Department of Gastroenterology of Zhongnan Hospital of Wuhan University between December 2016 and October 2017 were included in this study. The diagnosis of IBD was made bases on a combined assessment of clinical features, endoscopic findings, histopathological findings, and results of follow-up evaluation, including response to medical therapy, such as corticosteroids, immunomodulators, and/or antitumor necrosis factor-α (TNF-α) biologics. All patients were informed and consented to the study. All research processes were carried out in accordance with relevant guidelines and ethics regulations and with approval from Zhongnan Hospital of Wuhan University, approval number: 2022104K.

2.2. Inclusion and Exclusion Criteria. The inclusion criteria were as follows: (1) diagnosed with IBD; (2) patients have undergone both endoscopic examination and intestinal barrier function detection; (3) the interval between endoscopic examination and intestinal barrier function was less than 3 weeks. The exclusion criteria were as follows: (1) patients who had previous surgery of bowel resection; (2) patients who had taken nonsteroidal anti-inflammatory drug (NSAID) in the previous 3 weeks; (3) patients with specific pathogens infection (such as HIV, hepatitis B, syphilis, and salmonella), renal failure, chronic liver, colorectal cancer, connective tissue diseases, or pancreatitis.

2.3. Protocol. Endoscopic disease activity was, respectively, scored by experienced endoscopist using the Simple Endoscopic Score for Crohn’s Disease (SES-CD) or the ulcerative colitis endoscopic index of severity (UCEIS) [16, 17].

D-lactate, DAO, and ETX in the blood were colored by diamine oxidase, lactic acid, bacterial endotoxin assay kit (Enzyme), which was provided by Beijing Zhongsheng Jinyu Diagnostic Technology Ltd., China. Then, the stained samples were detected and quantified by JY-DLT Intestinal barrier function biochemical index analysis system.

2.4. Definitions of Variables. The “Big Ulcer” was defined as their longest diameter more than 20 mm, the “Small ulcers” were defined as whose longest diameter less than 5 mm. The calculation of SES-CD was based on four endoscopic variables (presence and size of ulcers, proportion of surface covered by ulcers, proportion of surface affected by disease, and presence and severity of stenosis) and assessed in 5 ileocolonic segments. Vascular pattern, bleeding, and erosions or ulcerations were evaluated in the most inflamed colonic segment to calculate the UCEIS. The SES – CD ≤ 2 or UCEIS ≤ 1 were defined as remission. For active CD, we defined SES-CD 3-6 as mild activity, 7-15 as moderate activity, and score ≥ 16 as severe activity. For active UC patients, we defined UCEIS 2-6 as mild and moderate activity and 7-8 as severe activity.

2.5. Statistical Analysis. Statistical analysis was performed using the SPSS 21.0 software (SPSS, Chicago, IL, USA) and GraphPad Prism 5.0 software (GraphPad Software Inc., La Jolla, CA, USA). Correlation between categorical variables were determined by Pearson correlation coefficient r. Receiver operating characteristic (ROC) analysis was used to find the optimal thresholds of the DAO, D-lactate, and ETX for discriminating endoscopic activity in patients with IBD. The optimal diagnostic thresholds for a test were determined by plotting Youden’s index (YI = [sensitivity + specificity] – 1). The area under the curve (AUC) was used to compare accuracies of biomarkers in predicting different endoscopic severity. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy (proportion of correct diagnoses) were calculated to determine the reliability of each of the biomarkers to predict endoscopic severity in patients with IBD.

3. Results

3.1. Patient Baseline Characteristics. A total of 149 eligible patients (82 CD, 67 UC) were enrolled, 134 patients (73 CD, 61 UC) were in active, and 15 patients (9 CD, 6 UC) were in remission. The baseline characteristics of all patients were shown in Table 1. The median disease duration of all patients was 3 years (interquartile range [IQR]:1.0–4.0 yr). The patients with CD were younger than UC (median age 28.0 vs. 46.0 years, P < 0.001). There was no statistical difference in gender and smoking history between patients with UC and CD. Based on the Montreal classification, most of the patients with CD (55.65%) had an ileocolonic disease (L3), and 64.18% of the patients with UC had an extended colitis (E3).

3.2. Correlation between Biomarkers and Endoscopic Score in CD Patients. Correlation coefficient r between biomarkers and endoscopic score of disease severity of CD was shown in Table 2. As shown in the table, DAO and ETX were demonstrated to have a better correlation with SES-CD (r = 0.532 and r = 0.468, respectively; P < 0.0001 for both) compared to WBC, ESR, and CRP (r = 0.146, P = 0.191; r = 0.346, P = 0.0015; r = 0.250, P = 0.023), while there was no correlation between D-lactate and SES-CD (r = 0.167, P = 0.133).

3.3. Correlation between Biomarkers and Endoscopic Score in UC Patients. Correlation coefficient r between biomarkers
and endoscopic score of disease severity of UC were shown in Table 3. Similar to CD, DAO and ETX were demonstrated to have better correlation with UCEIS (\(r = 0.600\) and \(r = 0.505\), respectively; \(P < 0.0001\) for both) compared with WBC, ESR, and CRP (\(r = 0.151, P > 0.05\); \(r = 0.285, P = 0.021\); \(r = 0.334, P = 0.006\)). There was significant but weak correlation between D-lactate and UCEIS (\(r = 0.407, P = 0.0006\)). The relationship of DAO, D-lactate, and ETX with endoscopic score of UC were shown to be better than those of CD.

**3.4. Value of Intestinal Barrier Marker in Predicting Endoscopic Severity in CD.** As was shown in Table 4 and Figure 1, the DAO levels of severe groups were higher than those of moderate groups \((P < 0.05, \text{Figure 1(a))}\), and the DAO levels of moderate groups were also higher than those of mild groups \((P < 0.001, \text{Figure 1(a))}\). The ETX levels of severe groups were higher than those of moderate groups \((P < 0.05, \text{Figure 1(b))}\), and the ETX levels of moderate groups were also higher than those of mild group \((P < 0.01, \text{Figure 1(b))}\). In brief, as severity of endoscopy increased, the levels of DAO and ETX increased. There was no difference in D-lactate levels among three groups of active CD patients (Figure 1(c)).

The DAO and ETX had diagnostic utility in differentiating CD patients with different endoscopic activities (Figure 2 and Table 4). For DAO, the optimum discriminative cutoff threshold for distinguishing endoscopic mild disease was 18.54 u/L, with an AUC of 0.80, \(P < 0.001\) (sensitivity 71.93%, specificity 71.93%, PPV 87.2%, NPV 54.3%, and accuracy 71.95%). For ETX, the optimum discriminative cutoff threshold for distinguishing endoscopic mild disease was 18.63 u/L, \(P < 0.001\) (sensitivity 71.93%, specificity 71.93%, PPV 87.2%, NPV 54.3%, and accuracy 71.95%). Further research has found that the optimum discriminative cutoff of DAO threshold for severe disease in CD (SES – CD ≥ 16) was 18.63 U/L \((P = 0.75, \text{AUC} = 0.001\)). The test parameters of DAO were as follows: sensitivity 89.47%, specificity 53.79%, PPV 37.0%, NPV 94.4%, and accuracy 75.0%. For ETX, the optimum discriminative cutoff threshold for distinguishing endoscopic mild disease was 10.51 u/L, \(P = 0.76\) (sensitivity 70.18%, specificity 80.0%, corresponding PPV, NPV, and accuracy were 88.9%, 54.1%, and 73.3%, respectively. Further research has found that the optimum discriminative cutoff of DAO threshold for severe disease in CD (SES – CD ≥ 16) was 18.63 U/L \((P = 0.75, \text{AUC} = 0.001\)). The test parameters of ETX were as follows: sensitivity 89.47%, specificity 53.79%, PPV 37.0%, NPV 94.4%, and accuracy 71.95%. For ETX, the optimum discriminative cutoff threshold for severe disease was 22.38 U/L \((P = 0.76\), sensitivity 57.89%, specificity 82.54%, PPV 50.0%, NPV 86.7%, and accuracy 76.83%, respectively), and the AUC was 0.70, \(P = 0.010\) (SES – CD ≥ 16). The D-lactate, as well as WBC, ESR, or CRP, failed to assess endoscopic severity in CD \((P > 0.05\) for all).
3.5. Value of Intestinal Barrier Marker in Predicting Endoscopic Remission in CD. Although we have demonstrated that DAO and ETX were positively correlated with SES-CD, there was no statistically significant difference in the level of DAO, D-lactate, and ETX between active and inactive groups in CD patients ($P > 0.05$; Table 5). The multivariate analyses demonstrated that no optimal threshold could be identified that distinguished active CD from inactive CD, as the NPV of test was not satisfied (Figure 3 and Table 6).

3.6. Value of Intestinal Barrier Marker in Predicting Endoscopic Severity in UC. In active UC patients, mild and moderate activity was merged into one group. There was no significant difference in DAO and D-lactate between mild-moderate and severe patients ($P > 0.05$ for both, Figure 4), and only levels of ETX for severe group were higher than mild-moderate group ($P < 0.05$, Figure 4). The result is quite different with CD. ROC curve analysis was shown in Figure 5 and Table 7. No endoscopic disease category was individually distinguishable by DAO, D-lactate, ETX, WBC, ESR, and CRP. Although the levels of ETX of severe group were higher than mild-moderate group, we have not found an optimum discriminative cutoff of ETX to distinguish the severity of endoscopy.

3.7. Value of Intestinal Barrier Marker in Predicting Endoscopic Remission in UC. Significant differences were found in DAO, D-lactate, and ETX levels between active and inactive UC patients ($P = 0.004, P = 0.008$, and $P = 0.003$; Table 8). On the whole, the levels of DAO, D-lactate, and ETX of the active group were higher than that of the inactive group ($UCEIS \leq 1$). ROC analysis shown that DAO, D-lactate, and ETX have a certain diagnostic utility in predicting endoscopic remission (Table 9 and Figure 6). The AUC of DAO for endoscopic disease thresholds of $UCEIS \leq 1$ was $0.86$, $P < 0.001$. The optimum discriminative cutoff of DAO threshold was $15.97$ U/L, predicting endoscopic remission with $83.93\%$ sensitivity and $90.91\%$ specificity; the PPV, NPV, and accuracy of this threshold were $97.9\%, 52.6\%$, and $85.07\%$. The AUC for D-lactate and ETX for endoscopic disease thresholds of $UCEIS \leq 1$ was $0.80$, $P = 0.002$ and $0.80$, $P = 0.002$, the corresponding cutoff of D-lactate and ETX is $36.53$ mg/l and $17.55$ U/L. The sensitivity, specificity, PPV, NPV, and accuracy of D-lactate in predicting remission of this thresholds are $75\%, 81.82\%, 95.5\%, 39.1\%$, and $76.12\%$. The sensitivity, specificity, PPV, NPV, and accuracy of ETX in predicting remission of this thresholds are $62.5\%, 92.91\%, 97.2\%, 32.3\%$, and $67.16\%$. We further repeated the experiment, and the results showed that if $UCEIS = 0$ was defined as remission, there was no statistically significant difference in the level of DAO, D-lactate, and ETX of UC patients with active patients ($P > 0.05$). ROC curve analysis also showed that DAO, D-lactate, and ETX could not predict endoscopic UC remission when $UCEIS = 0$ was defined as remission.

4. Discussion

The activity of IBD is closely related to readmission rates and prognosis of patients and leading to significant increases in morbidity and mortality. In patients with inflammatory bowel disease, endoscopy plays a key role in the assessment of disease activity, disease recurrence, treatment response, dysplasia surveillance, and delivery of endoscopic therapy [18]. Although less invasive biomarkers are in development, diagnosis still relies on endoscopy and histological assessment of biopsy specimens [19]. It is quite a difficult task to find an accurate, reliable, and reproducible noninvasive biomarker to replace endoscope. Currently, DAO, D-lactate, and ETX are used to evaluate the function of the intestinal barrier which plays an important role in the development of IBD by assessing intestinal permeability changes, intestinal bacterial migration, and intestinal injury [20]. In this study, we evaluated the correlation between DAO, D-lactate, ETX, and IBD endoscopic score, as well as their value as alternative markers in predicting IBD endoscopic activity and remission. Our results showed that DAO and ETX are positively correlated with SES-CD in CD patients, but D-lactate is not significantly correlated with SES-CD. In UC, DAO, D-lactate, and ETX are also positively correlated with $UCEIS$. In addition, we found that DAO, D-lactate, and ETX could be used to distinguish endoscopic severity of CD patients to some degree, as well as that DAO, D-lactate, and ETX could be used to distinguish endoscopic remission in UC patients.
Diamine oxidase (DAO) is an enzyme mainly located in villus tip enterocytes of humans and other mammals, which mainly expressed in intestinal mucosal. The level of DAO in peripheral blood is usually very low. The DAO would release into the circulation when the intestinal mucosal cells were damaged, resulting in the increase of DAO in blood. Several previous researches of humans and rats have suggested that its activity reflected the integrity of intestinal mucosa [21], as well as injury and recovery [22, 23]. In humans, D-lactate is mainly produced by metabolism of indigenous bacteria in the gastrointestinal tract. Studies indicated that mammals are not equipped with efficient enzyme systems to metabolize D-lactate [24, 25]. As a consequence, D-lactate tends to be maintained at low levels in healthy individuals. When the intestinal mucosa barrier was injured, D-lactate could be released to the blood through the dysfunctional intestinal barrier, leading to the increase of serum D-lactate. Endotoxin (ETX) is the outer membrane of gram-negative bacteria cell walls of lipopolysaccharide (LPS), usually released after the death of a bacterium, as well as in the metabolic process. Intestinal tract is the body’s largest bacterial endotoxin storage, and endotoxin enters the blood circulation with unknown mechanism through the damaged intestinal mucosa barrier. A study of 18 CD patients suggested that the level of serum ETX was elevated during the acute exacerbation [26], and the consequence was confirmed by several other studies [27].

A study indicated that the levels of serum DAO and D-lactate are higher in IBD patients compared with those in healthy groups, and serum DAO and D-lactate could be decreased after treatment [28], suggesting that IBD patients suffer intestinal barrier dysfunction. In this study, DAO and ETX were found to be associated with CD endoscopy score (SES-CD) in patients with CD, and the correlation coefficient was superior to traditional inflammatory markers (WBC, ESR, and CRP). DAO, D-lactate, and ETX were significantly correlated with UCEIS in UC patients, and the correlation coefficient was also superior to traditional inflammatory markers. Our hypothesis was proved that DAO, D-lactate, and ETX showed significant intestinal specificity compared with traditional inflammatory markers (WBC, ESR, and CRP). The verification could explain that why DAO, D-lactate, and ETX were more correlated with IBD endoscopic score than traditional inflammatory markers. At the same time, our results showed that DAO, D-lactate, and ETX were more correlated.
failed to predict CD endoscopy severity. However, it is worth noting that our results showed no significant correlation between D-lactate and SES-CD. In addition, due to the limitation of retrospective study, changes in DAO, D-lactate, and ETX levels and their correlation with endoscopic scores after treatment have not been studied, which requires further prospective studies.

In the study of patients with different endoscopic activity levels (severity), our results showed that in patients with CD, DAO level in patients with severe activity is higher than that in patients with moderate activity, and DAO level in patients with moderate activity is also higher than that in patients with mild activity. The same was true for the analysis in EXT. Overall, DAO and ETX levels showed an upward trend with the increase of endoscopic activity. However, there were no statistically significant differences in D-lactate levels among CD patients with mild, moderate, and severe activity, which was consistent with the correlation analysis results, suggesting that CD patients with high levels of DAO and ETX tend to be with more severe endoscopic activities.

Further analysis suggested that DAO and ETX have certain diagnostic value in distinguishing CD patients with different endoscopic activity. ROC curves showed that DAO and ETX could be used to distinguish moderate and severe endoscopic activity. The thresholds for identifying endoscopic moderately active patients with mild activity were 18.54 U/L (sensitivity 71.93% and specificity 71.93%) and 10.51 U/L (sensitivity 70.18% and specificity 80.0%). The best discriminant threshold for identifying DAO thresholds for patients with severe activity was 18.63 U/L (sensitivity 89.47% and specificity 53.79%). For ETX, the threshold for predicting patients with severe activity was 22.38 U/L (sensitivity 57.89%, and specificity was 82.54%). D-lactate was unable to assess the different activities of endoscopy in the CD, which was consistent with the results of the correlation analysis. Salim and Soderholm [12] believed that intestinal mucosal barrier is severely damaged during acute IBD attack, resulting in structural and functional destruction, and subsequently, increased permeability and tissue damage. A study of 18 CD patients showed elevated levels of ETX during acute episodes in CD patients [26]. Our research confirmed this point, and it also indicated that patients with high levels of DAO and ETX are prone to be associated with more serious endoscopic activities.

Although DAO and ETX are proved to be positively correlated with SES-CD in this study, when SES – CD ≤ 2 was defined as endoscopic remission, the difference between DAO and ETX among patients with activity and remission was not statistically significant. ROC curve analysis also

Table 5: Intestinal barrier markers and inflammatory markers in remission and active CD patients.

| Remission (SES – CD ≤ 2) | Active (SES – CD > 2) | P     |
|-------------------------|-----------------------|-------|
| DAO (U/L)               | 16.06 ± 12.46         | 28.63 ± 20.35 | 0.075 |
| D-lactate (mg/l)        | 37.78 ± 22.94         | 37.82 ± 19.84 | 0.997 |
| ETX (U/L)               | 9.37 ± 5.51           | 16.46 ± 13.05 | 0.113 |
| WBC (10^9/L)            | 5.21 ± 1.48           | 6.62 ± 2.55   | 0.109 |
| ESR (mm/h)              | 9.67 ± 14.92          | 26.39 ± 26.34 | 0.066 |
| CRP (mg/L)              | 9.87 ± 12.41          | 28.55 ± 30.17 | 0.071 |

with UC endoscopic score than CD. However, it is worth noting that our results showed no significant correlation between D-lactate and SES-CD. In addition, due to the limitation of retrospective study, changes in DAO, D-lactate, and ETX levels and their correlation with endoscopic scores after treatment have not been studied, which requires further prospective studies.
showed that DAO and ETX could not identify remission and activity ($P > 0.05$). There was no statistical difference in D-lactate level between patients with activity and remission, and ROC curve analysis also showed that D-lactate has no diagnostic value in predicting endoscopic remission at SES–CD $\leq 2$. Thus, no threshold was found for the best intestinal barrier marker to distinguish CD activity from remission. Pastor Rojo et al. [27] found that the serum endotoxin level increased in IBD patients, although decreased after treatment, ETX did not fully return to normal levels in CD patients. The reason may be related to the recovery degree of intestinal barrier function in patients with remission. Several studies suggested that patients in remission stage are capable of being associated with increased intestinal permeability [29, 30]. Combined with our study, the possible cause is that the intestinal barrier function of CD patients is still not fully recovered, although the intestinal mucosa heals after treatment. Chang et al. [31] found that the degree of intestinal permeability damage is related to the severity of diarrhea, therefore, not only mucosal healing should be included in the final treatment goal of IBD but also the recovery of intestinal barrier function. Some studies showed that CD patients with increased intestinal permeability in remission stage also have an increased risk of disease recurrence [32]. Although DAO and ETX were not proved to be valuable in predicting endoscopic remission of CD, our study demonstrated that further therapy for intestinal barrier was still needed in CD patients at endoscopic remission stage. Continuous treatment is capable of being helpful for reducing CD recurrence and maintaining longer remission period.

However, in UC patients with different endoscopic activity, there was no significant difference in DAO and D-lactate between the mild moderate activity group and the severe group, but the ETX levels of severe group were significantly higher compared with the mild-moderate group. Although high level of ETX tended to be associated with more serious endoscopic activity, we did not detect the best ETX discriminant threshold. Correlation analysis showed that DAO, D-lactate, and ETX were correlated with UCEIS up to a point, but with the increase of endoscopic severity, the levels of DAO, D-lactate, and ETX increased not as obvious as CD. This may be related to the fact that UC is a lesion limited to submucosa, and CD is a transmural lesion of whole mucosa.
Therefore, when distinguishing endoscopic relief from activity, ROC curve analysis showed that DAO, D-lactate, and ETX could predict endoscopic UC relief ($\text{UCEIS} \leq 1$). There were significant differences in DAO, D-lactate, and ETX levels between UC patients with activity ($\text{UCEIS} > 1$) and remission ($\text{UCEIS} \leq 1$) ($P = 0.004$, $P = 0.008$, and $P = 0.003$); and DAO, D-lactate, and ETX levels in the active group were significantly higher than those in the remission group. The best prediction boundary of DAO between activity ($\text{UCEIS} > 1$) and remission ($\text{UCEIS} \leq 1$) was 15.97 U/L, with a sensitivity of 83.93% and specificity of 90.91% for predicting endoscopic remission and an accuracy of 85.07%. The best predictive values of D-lactate and ETX for activity ($\text{UCEIS} > 1$) and remission ($\text{UCEIS} \leq 1$) were 36.53 mg/l (sensitivity 75% and specificity 81.82%) and 17.55 U/l (sensitivity 62.5% and specificity 92.91%), with an accuracy of 76.12% and 67.16%, respectively. Further repeated analysis was performed at $\text{UCEIS} = 0$ and $\text{UCEIS} \leq 2$, and the results also fell short of expectations.

Combined with correlation analysis and detection analysis results of different activity levels, although DAO, D-lactate, and ETX could not distinguish UC endoscopic activity level, our study showed that UC patients with low level DAO, D-lactate, and ETX were more inclined to endoscopic remission. Pastor Rojo et al. [27] found that endotoxin levels were reduced in patients with IBD after treatment, but CD patients did not fully return to normal levels. Part of the description

**Figure 4:** In active UC patients, there was no significant difference in DAO and D-lactate between mild-moderate and severe patients ($P > 0.05$ for both), while ETX levels of severe group were higher than mild-moderate group ($P < 0.05$).

**Figure 5:** The ROC curves of DAO, D-lactate, ETX, and inflammatory markers for detecting the severity of UC endoscopy showed that the above indicators failed to distinguish the endoscopic severity of UC.
showed that compared with CD, UC patients are more likely to achieve recovery of intestinal barrier function during remission, which is subject to further prospective trials. Our research showed that DAO, D-lactate, and ETX have good predictive value of endoscopic remission in UC and have potential application value in clinical.

To sum up, not only endoscopic examination, biomarkers are of great importance to assessing IBD progress. Our study found that DAO, D-lactate, and ETX are significantly correlated with UCEIS score in UC patients, and the correlation coefficient was better than traditional inflammatory markers WBC, ESR, and CRP. We also found that in patients with CD, DAO, and ETX not only showed better correlation with SES-CD than WBC, ESR, and CRP but also could distinguish different endoscopic activities. Due to the influence of sample size and the nature of retrospective study, our study still has some limitations. Further prospective trials are necessary in the future. It is of great significance for clinical practice to develop treatment strategies and predict prognosis.

### Data Availability

All data used during the study appear in the submitted article.

### Disclosure

A preprint has previously been published [33].

### Conflicts of Interest

The authors declare no conflicts of interest.

### Authors’ Contributions

Min Chen, Qi Zhang, and Jixiong Wu contributed to the conception of the study; Qi Zhang and Xin Gao performed the data collection and analyses and wrote the manuscript. All authors reviewed the manuscript. Qi Zhang and Xin Gao contributed equally to this work.

### Acknowledgments

This study was supported by the Medical Science and Technology Innovation Project (no. PTXM2021013).
References

[1] F. Baert, L. Moortgat, G. Van Assche et al., “Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease,” *Gastroenterology*, vol. 138, no. 2, pp. 463–468, 2010.

[2] M. Boirivant, M. Leoni, D. Taricciotti, S. Fais, O. Squarizia, and F. Pallone, “The clinical significance of serum C-reactive protein levels in Crohn’s disease,” *Journal of Clinical Gastroenterology*, vol. 10, no. 4, pp. 401–405, 1988.

[3] C. Niederau, F. Backnerhoff, B. Schumacher, and C. Niederau, “Inflammatory mediators and acute phase proteins in patients with Crohn’s disease and ulcerative colitis,” *Hepato-Gastroenterology*, vol. 44, no. 13, pp. 90–107, 1997.

[4] P. Miranda-Garcia, M. Chaparro, and J. P. Gisbert, “Correlation entre los marcadores biologicos y la actividad endoscopica en pacientes con enfermedad inflamatoria intestinal,” *Gastroenterologia y Hepatologia*, vol. 39, no. 8, pp. 508–515, 2016.

[5] J. Y. Yoon, S. J. Park, S. P. Hong, T. I. Kim, W. H. Kim, and J. H. Cheon, “Correlations of C-reactive protein levels and erythrocyte sedimentation rates with endoscopic activity indices in patients with ulcerative colitis,” *Digestive Diseases and Sciences*, vol. 59, no. 4, pp. 829–837, 2014.

[6] A. M. Schoepfer, S. Vavricka, N. Zahnd-Straumann, A. Straumann, and C. Beglinger, “Monitoring inflammatory bowel disease activity: clinical activity is judged to be more relevant than endoscopic severity or biomarkers,” *Journal of Crohn’s & Colitis*, vol. 6, no. 4, pp. 412–418, 2012.

[7] I. Bjarnason, A. MacPherson, and D. Holland, “Intestinal permeability: An overview,” *Gastroenterology*, vol. 108, no. 5, pp. 1566–1581, 1995.

[8] F. Scaldaferrì, M. Pizziottara, V. Gerardi, L. Lopetuso, and A. Gasbarrini, “The gut Barrier: new acquisitions and therapeutic approaches,” *Journal of Clinical Gastroenterology*, vol. 46, pp. S12–S17, 2012.

[9] L. Antoni, S. Nuding, J. Wehkamp, and E. F. Stange, “Intestinal barrier in inflammatory bowel disease,” *World Journal of Gastroenterology*, vol. 20, no. 5, pp. 1165–1179, 2014.

[10] J. Wyatt, H. Vogelsang, W. Hubl, T. Walldhoer, and H. Lochs, “Intestinal permeability and the prediction of relapse in Crohn’s disease,” *The Lancet*, vol. 341, no. 8858, pp. 1437–1439, 1993.

[11] H. Vogelsang, “Do changes in intestinal permeability predict disease relapse in Crohn’s disease?,” *Inflammatory Bowel Diseases*, vol. 14, Suppl 2, pp. S162–S163, 2008.

[12] S. Y. Salim and J. D. Soderholm, “Importance of disrupted intestinal barrier in inflammatory bowel diseases,” *Inflammatory Bowel Diseases*, vol. 17, no. 1, pp. 362–381, 2011.

[13] J. Cai, H. Chen, M. Weng, S. Jiang, and J. Gao, “Diagnostic and clinical significance of serum levels of D-lactate and d-mannomanno-and C-reactive protein: a meta-analysis in patients with Crohn’s disease,” *Gastroenterology Research and Practice*, vol. 2019, Article ID 8536952, 7 pages, 2019.

[14] K. R. Gardiner, M. I. Halliday, G. R. Barclay et al., “Significance of systemic endotoxaemia in inflammatory bowel disease,” *Gut*, vol. 36, no. 6, pp. 897–901, 1995.

[15] K. Champion, L. Chiu, J. F. J. Ferbas, and M. Pepe, “Endotoxin neutralization as a biomonitor for inflammatory bowel disease,” *PLoS One*, vol. 8, no. 6, article e67736, 2013.

[16] S. P. Travis, D. Schnell, P. Krzeski et al., “Developing an instrument to assess the endoscopic severity of ulcerative colitis: the ulcerative colitis endoscopic index of severity (UCEIS),” *Gut*, vol. 61, no. 4, pp. 535–542, 2012.

[17] M. Daperno, G. D’Haens, G. Van Assche et al., “Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD,” *Gastrointestinal Endoscopy*, vol. 60, no. 4, pp. 505–512, 2004.

[18] B. Shen, G. S. Kochhar, U. Navaneethan et al., “Endoscopic evaluation of surgically altered bowel in inflammatory bowel disease: a consensus guideline from the Global Interventionsal Inflammatory Bowel Disease Group,” *The Lancet Gastroenterology & Hepatology*, vol. 6, no. 6, pp. 482–497, 2021.

[19] G. Roda, S. Chien Ng, P. G. Kotze et al., “Crohn’s disease,” *Nature Reviews. Disease Primers*, vol. 6, no. 1, 2020.

[20] S. Mehandru and J. F. Colombel, “The intestinal barrier, an arbitrator turned provocateur in IBD,” *Nature Reviews. Gastroenterology & Hepatology*, vol. 18, no. 2, pp. 83-84, 2021.

[21] G. D. Luk, T. M. Bayless, and S. B. Baylin, “Diamine oxidase (histaminase). A circulating marker for rat intestinal mucosal maturation and integrity,” *The Journal of Clinical Investigation*, vol. 66, no. 1, pp. 66–70, 1980.

[22] G. D. Luk, W. P. Vaughan, P. J. Burke, and S. B. Baylin, “Diamine oxidase as a plasma marker of rat intestinal mucosal injury and regeneration after administration of 1beta-D-arabinofuranosylcytosine,” *Cancer Research*, vol. 41, no. 6, pp. 2334–2337, 1981.

[23] L. D’Agostino, S. Pignata, B. Daniele et al., “Postheparin plasma diamine oxidase values in the follow up of patients with small bowel Crohn’s disease,” *Gut*, vol. 32, no. 8, pp. 932–935, 1991.

[24] S. M. Smith, R. H. Eng, J. M. Campos, and H. Chmel, “D-lactic acid measurements in the diagnosis of bacterial infections,” *Journal of Clinical Microbiology*, vol. 27, no. 3, pp. 385–388, 1989.

[25] C. Nielsen, F. V. Mortensen, J. E. Erlandsen, and J. S. Lindholt, “L- and d-lactate as biomarkers of arterial-induced intestinal ischemia: an experimental study in pigs,” *International Journal of Surgery*, vol. 10, no. 6, pp. 290–300, 2012.

[26] W. Wellmann, P. C. Fink, B. Benner, and F. W. Schmidt, “Endotoxaemia in active Crohn’s disease. Treatment with whole gut irrigation and 5-aminosalicylic acid,” *Gut*, vol. 27, no. 7, pp. 814–820, 1986.

[27] Ő. P. Rojo, A. L. S. Román, E. A. Arbizu, A. de la Hera Martínez, E. R. Sevillano, and A. A. Martínez, “Serum lipopolysaccharide-binding protein in endotoxemic patients with inflammatory bowel disease,” *Inflammatory Bowel Diseases*, vol. 13, no. 3, pp. 269–277, 2007.

[28] W. B. Song, Y. H. Ly, Z. S. Zhang et al., “Soluble intercellular adhesion molecule-1, D-lactate and d-mannose in patients with inflammatory bowel disease,” *World Journal of Gastroenterology*, vol. 15, no. 31, pp. 3916–3919, 2009.

[29] M. Vivinus-Nébot, G. Frin-Mathy, H. Bizoueche et al., “Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation,” *Gut*, vol. 63, no. 5, pp. 744–752, 2014.

[30] W. Turpin, S. H. Lee, J. A. Raygoza Garay et al., “Increased intestinal permeability is associated with later development of Crohn’s disease,” *Gastroenterology*, vol. 159, no. 6, pp. 2092–2100, 2020.
[31] J. Chang, R. W. Leong, V. C. Wasinger, M. Ip, M. Yang, and T. G. Phan, "Impaired intestinal permeability contributes to ongoing bowel symptoms in patients with inflammatory bowel disease and mucosal healing," *Gastroenterology*, vol. 153, no. 3, pp. 723–731.e1, 2017.

[32] I. D. Arnott, K. Kingstone, and S. Ghosh, "Abnormal intestinal permeability predicts relapse in inactive Crohn disease," *Scandinavian Journal of Gastroenterology*, vol. 35, no. 11, pp. 1163–1169, 2000.

[33] https://www.researchsquare.com/article/rs-97722/v1.